Contract Manufacturing Industry News

  1. Aptuit SSCI To Hold Solid State Chemistry Short Course At The University Of Chicago 8/24/2012

    SSCI Inc., A Division of Aptuit, will be offering “Pharmaceutical Solids: Essential Knowledge and Advanced Concepts,” a two-day Pharmaceutical Solids Short Course for drug development scientists and related professionals.

  2. Industry And Academic Pros Attract More Than 150 Participants At Aptuit Science Day In Verona, Italy 8/24/2012

    Stuart Needleman, President and Chief Operating Officer, Aptuit LLC, expressed appreciation to guests and presenters who participated in the second annual Science Day Event at The Aptuit Center for Drug Discovery & Development in Verona, Italy on May 16, 2012. “Once again, we were able to share a lively exchange of ideas in response to the insightful presentations delivered by distinguished members of the industry and academia,” he said.

  3. Almirall And Quintiles Sign Long-Term Commercial UK Partnership 7/30/2012

    Almirall and Quintiles have reached a long-term strategic partnership agreement to promote Almirall’s respiratory portfolio in the UK commencing with a new, long-acting antimuscarinic (LAMA) delivered via an innovative, multi-dose inhaler for the treatment of chronic obstructive pulmonary disease (COPD).

  4. Parexel Launches The Parexel Biopharm Unit To Meet The Critical Development Goals Of Small And Mid-Sized Biopharmaceutical Companies 7/24/2012

     PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the launch of the PAREXEL BioPharm Unit – a dedicated unit within PAREXEL focused solely on the unique needs of small and mid-sized biopharmaceutical companies to help them achieve their development goals.

  5. ScinoPharm to Provide Contract Manufacturing Services For VIVUS' Newly-Approved Anti-Obesity Drug, Qsymia™ 7/24/2012

    ScinoPharm (TWSE:1789) announced today that its Tainan, Taiwan Facility will provide commercial manufacturing of topiramate active pharmaceutical ingredient (“API”) for VIVUS’ Qsymia™, a new drug for the treatment of obesity approved by the United States Food and Drug Administration on July 17, 2012.

  6. Abbott Announces New Test For The Management Of Patients With Diabetes 7/10/2012

    More than 346 million people worldwide are living with diabetes, and the World Diabetes Foundation estimates that number will increase by nearly 27 percent by 2030. In order to help physicians appropriately monitor treatment efficacy for these patients, Abbott announced recently CE Marking (Conformité Européenne) for the Abbott ARCHITECT HbA1c (IA) Assay.

  7. CPhI's Upcoming Conference Focuses On Advances In Pharma And Biopharma Drug Delivery 6/28/2012

    The NextGen India 2012: Advances in Pharma and Biopharma Drug Delivery conference will be held on July 25-27 in Mumbai. This conference will focus on bringing practical case studies from concept to commercialisation stages including orals, injectables, liposomes, sustained release depots, nanotechnology and solubility enhancing techniques.

     

  8. Catalent And Bend Research Partner To Provide Integrated Solutions For Oral Controlled-Release Technologies 6/21/2012

    Catalent Pharma Solutions, Inc. and Bend Research Inc. have entered into an agreement to provide integrated solutions for pharmaceutical companies seeking to develop and manufacture specialized multiparticulate oral controlled-release products.

  9. CPhI South America 2012 Returns To Brazil With One Of A Kind Pharma Event 6/19/2012

    Leading events organiser UBM Live, a division of UBM Plc, recently announced details of the fifth edition of CPhI South America which will take place from 21st to 23rd of August 2012 at the Transamérica Expo Center in São Paulo, Brazil. CPhI South America will once again be co-located with ICSE South America for outsourcing services and BioPh for companies working in biotechnical solutions. 

  10. DSM Announces Patent Grants For Proprietary XD Biomanufacturing Technology 6/19/2012

    DSM Biologics focuses on optimizing biopharmaceutical manufacturing through its unique set of technologies. The XD technology is an important building block in DSM’s vision for the future of biopharmaceutical manufacturing.